“Replek AD Skopje” concluded 2025 with increased profitability, strong market positions and continuous growth in sales results. The company achieved a visible improvement in profitability, generating a profit of 5 million euros, i.e. a growth of 39% compared to 2024. The net profit margin increased from 11.5% to 15%, which confirms the company’s ability to generate sustainable value and higher efficiency in operations, even in conditions of intensive investment activities.
The positive results achieved in 2025 are due to the company’s strategic approach, the effectiveness of cost management, and the changed approach to conquering new markets and strengthening the portfolio. As an export-oriented company, “Replek AD Skopje”, 75% of its revenues are generated from foreign markets, while the remaining 25% are generated on the domestic market. The company is present in 25 markets worldwide, and according to the business plan in the coming period, the company’s pharmaceutical portfolio will be present in 40 markets, i.e. 15 new markets. This will significantly strengthen the company’s positions, as well as the growth of revenues and profitability.
“The business results we achieved in 2025 are a clear confirmation that “Replek” is positioned as a strong and stable pharmaceutical company, with a clear vision for long-term growth and development. The successfully completed year is the result of the consistently implemented strategy of continuous investments in innovation, modernisation of production capacities and the courageous conquest of new markets, as well as the deepening of partnerships in existing ones. We are particularly encouraged by the fact that we manage to increase and maintain exports, which is the strongest proof that our products meet the highest international standards and are highly competitive, which is due to the dedication and professionalism of the entire “Replek” team. It is in the conquest of new markets, which we are working on with dedication, that we see the greatest potential for growth. We remain strongly committed to new investments in technologies, people and knowledge and continue to be a company that creates long-term values for the community and the national economy,” said Dushan Pecovski, CEO of “Replek”.
The total sales revenue of “Replek” in the period from January 1 to December 31, 2025 amounted to 34 million euros, which represents an increase of 8% compared to 2024, and is evidence of the company’s continued growth dynamics and stable market presence. From sales on the domestic market, “Replek” realised revenues of 8.6 million euros, maintaining a strong position and continuous presence in key segments. Through export activities, the company achieved revenues of 25.4 million euros, confirming its positions on foreign markets.
Last year, Replek successfully implemented the new ERP system with the transition to SAP S/4HANA, which improved the efficiency and control of business processes. The company made a significant investment in a new modern manufacturing block according to the highest pharmaceutical standards, which modernised and automated the manufacturing process and increased the capacity for primary and secondary packaging of solid pharmaceutical forms by 25%. The investment included a state-of-the-art technological line with advanced systems and artificial intelligence for real-time quality control. In addition, nine new products were successfully launched on the market, which enriched the offer for consumers and strengthened the innovation and flexibility of the company.
Looking ahead, Replek will continue to focus on strengthening its market presence, achieving sustainable sales growth and continuously improving profitability in order to create long-term value for its shareholders. The Company remains committed to maintaining the highest standards of corporate transparency, a commitment that has become even more significant following its inclusion in the MBI10 Index of the Macedonian Stock Exchange. This commitment was further recognised through the Most Transparent Company Award, presented by the Macedonian Stock Exchange in a vote by journalists, reaffirming Replek’s dedication to the highest standards of corporate transparency, accountability and investor relations.